Autosomal Recessive Polycystic Kidney Disease Clinical Trials

7 clinical trials for Autosomal Recessive Polycystic Kidney Disease across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD). — RECRUITING · PHASE3
• ARPKD Database Study — RECRUITING
• Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders — RECRUITING
• Imaging Assessments of ARPKD Kidney Disease Progression — RECRUITING
• National Registry of Rare Kidney Diseases — RECRUITING
• A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) — WITHDRAWN · PHASE3
• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD). — OTHER · PHASE3

Refine this search